Table 1.
Baseline characteristics of the cross-sectional cohort
| Group | Control (n = 7) | HF (n = 12) | HTx (n = 12) | P-value (overall) |
|---|---|---|---|---|
| Age (years) | 42 ± 14 | 52 ± 16 | 47 ± 18 | >0.2 |
| Gender n (%) | ||||
| Male | 5 (71%) | 10 (83%) | 11 (92%) | >0.2 |
| Female | 2 (29%) | 2 (17%) | 1 (8%) | |
| BMI (kg/m2) | 27.8 ± 4.2 | 23.1 ± 3.1 | 31.5 ± 5.5 | <0.001 |
| Cachexia presenta | NA | 7 (58%) | NA | NA |
| Diabetes | 0 | 3 (25%) | 2 (17%) | NA |
| Weight gain since HTx (kg) | NA | NA | 18.0 ± 7.7 | NA |
| Time since HTx (months) | NA | NA | 12.7 ± 8.6 | NA |
| Aetiology | ||||
| Ischaemic | NA | 4 (33%) | 6 (50%) | >0.2 |
| Dilated | 6 (50%) | 5 (42%) | ||
| Valvular | 2 (17%) | 1 (8%) | ||
| HF drug therapy | ||||
| Loop diuretic | NA | 12 (100%) | NA | NA |
| ACE-inhibitor | 12 (100%) | |||
| Beta-blocker | 5 (42%) | |||
| Inotropes | 7 (58%) | |||
| HTx drug therapy | ||||
| Prednisone (mg) | NA | NA | 6 ± 4 | NA |
| Cyclosporine A | 9 (75%) | |||
| Tacrolimus | 3 (25%) | |||
| Mycophenolate mofetil | 12 (100%) | |||